Study Overview: This research is a follow-up trial to evaluate how safe and effective it is to use a medicine called Defibrotide for patients with sickle cell disease or beta thalassemia who are getting a special type of stem cell transplant. These patients are at risk for a liver problem called sinusoidal obstructive syndrome (SOS), and Defibrotide might help prevent it.
Key Terms:
- **Myeloablative Conditioning**: A strong treatment to prepare the body for a stem cell transplant.
- **Haplo AlloSCT**: A stem cell transplant using a family member who is a half-match.
- **Defibrotide Prophylaxis**: Using Defibrotide medicine to prevent a disease.
- **CD34 Enrichment**: A way to make the stem cells used in the transplant more effective.
- **T-cell Addback**: Adding T-cells back into the body to help fight infections.
Key Points:
- This study involves a stem cell transplant and uses Defibrotide to help prevent liver problems.
- Participants must have specific complications from sickle cell disease or beta thalassemia to join.
- Women who are pregnant or breastfeeding cannot take part in this study.
How understandable was the trial content above?
Hard to understand
Easy to understand